SUBSCRIBE
IQVIA Blog Digest
For all the latest industry insights, please subscribe to the IQVIA U.S. blog digest.
-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
WHO WE HELP
-
Pharmaceutical Manufacturers
-
Emerging Biopharma
-
MedTech
-
Financial Institutions
-
Government and Public Health
-
Health Plans
-
Hospital and Health Systems
-
Insurers and Risk
-
Medical Specialty and Patient Advocacy
Pharmaceutical Manufacturers
Harness unparalleled healthcare data, advanced analytics, and cutting-edge technologies with our expertise to accelerate the development and commercialization of innovative medicines, enhancing patient lives.
Discover MorePharmaceutical Manufacturers
Emerging Biopharma (Global page)
Boost your innovation with IQVIA's expert team. Our comprehensive solutions integrate top-tier insights, technology, and expertise to maximize your asset's success in a competitive landscape.
Discover InnovationsMedTech
Navigating MedTech's unique landscape: U.S. decision-making now rests with GPOs, IDNs, and payers, who demand solid value proof through rigorous outcomes analyses and pricing scrutiny.
Explore MedTechMedTech
Financial Institutions
Invest in healthcare with confidence. Stay ahead of pharma and medical device trends using real-time, high-quality data. Access market insights, historical sales, prescription trends, and emerging product information for informed, risk-reduced decisions.
Access InsightsGovernment and Public Health
Unlock deeper health insights with unmatched data and innovative technology to enhance decision-making for your essential government programs.
Unlock InnovationsGovernment and Public Health
Health Plans
Accelerate digital innovation with our data-driven expertise in data science and healthcare, optimizing business processes for smarter decisions.
Navigate Health PlansHospital and Health Systems
Leverage digital innovation to cut costs, boost efficiency, and elevate patient engagement, all while enhancing quality and health outcomes.
Streamline DecisionsHospital and Health Systems
Insurers and Risk
Enhance your ability to evaluate and forecast population risk swiftly and accurately by integrating unmatched data, expertise, and technology.
Uncover More
Medical Specialty and Patient Advocacy
Transform into a data-driven organization that enhances your specialty and showcases value to your members through digital transformation.
Explore NowU.S. PROGRESS POINT
A curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the United States healthcare market.
LEARN MOREBLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTS
PODCASTS
"Discover the future through our enlightening podcasts available in the United States.
EXPLORE PODCASTSBlog
Real World Evidence Opportunities in Rare Disease
Mar 09, 2021
Pharma companies developing rare disease treatments face unique challenges in collecting real world evidence (RWE) data to support their initiatives. Real world studies of these diseases are limited by multiple factors: the prevalence of under/late diagnosis; the understanding of the disease being limited to a low number of specialists; and, patients being seen across a variety of settings—primary, secondary, and tertiary—by both primary care physicians and specialists.
The pervasiveness of healthcare data and the growing data fluency among regulators, payers, and other stakeholders, means that pharma companies now have a much wider range of options to use real world evidence (RWE) to support their development efforts.
In some cases, a combination of claims data, electronic medical records (EMR), and patient registries can be used to answer key research questions, even among small and dispersed patient populations.
Direct-to-patient studies, a ‘mosaic’ of combinations of clinical and real world components, and enriched studies that combine data collected from physicians and patients with secondary data are being deployed across rare diseases. These innovative RWE methods can provide a more comprehensive understanding of the patient journey and be used to identify patients and support more comprehensive diagnosis of these conditions.
Here are two examples of those innovations in action.
Algorithm finds cardiac patients
IQVIA recently partnered with a large pharma company that had a highly efficacious treatment for a rare cardiac disease treated by a small number of specialist centers in the UK. They wanted to provide support for patients in early diagnosis when treatment had a greater effect, but due to the rarity of the disease, the diagnostic coding in the hospital claims dataset was insufficient to identify these patients.
To find them, IQVIA built a machine learning algorithm to assess patterns of healthcare utilization and diagnoses in the UK’s national Hospital Episode Statistics (HES) records. Then the team linked EMR data from the leading specialist center to the national HES to define a precise cohort of patients and validate the findings. The analysis identified opportunities to accelerate diagnosis in certain regions, which led to the subsequent development of a predictive algorithm that eventually will be piloted to support screening efforts.
Oncology evidence generation
RWE can be especially useful in the competitive oncology market, where product differentiation and value demonstration are key. Pharma companies can use RWE to hone their R&D plans, accelerate launch, improve uptake, and differentiate their products in a crowded marketplace. However, they face multiple challenges, particularly in Europe where the quality and depth of data is limited, privacy restrictions limit access to data, and fragmented data systems and electronic medical records (EMR) limit comparative analysis opportunities.
IQVIA is mitigating these challenges by leveraging our data expertise and our relationships with key opinion leaders (KOLs), and our advanced analytics capabilities, to create disease specific networks that can be used across the drug development lifecycle. Their applications include
- Offering external comparators to support Health Technology Assessment (HTA) and regulatory submissions
- Using retrospective observational studies to run real time queries and bespoke analyses
- Using internal RWE studies to test protocol feasibility and hypotheses during clinical phases
- Honing differentiated value messaging for commercial applications
What study design is right for you?
RWE studies are a powerful tool to gather insights about hard-to-find patients. However, selecting the right RWE methodology and format is critical to generating the most value from these investments.
RWE studies generally fall into two categories:
- RWE studies based on broad coverage data sources. Studies using existing data from medical claims, pharmacy records, and ambulatory EMRs are generally quicker and less costly to execute, and provide generalized insights across large segments of the population, with limited specificity. They are useful for defining the patient journey, identifying population characteristics, and tracking patients across a region.
- RWE studies based on clinically rich sources. These studies provide detailed insights about specific populations, but they come from a much smaller number of patients (lower coverage) and can be costly and complicated to run. The data can come from specialty network databases, patient registries, specialty EMR, and studies custom built for a specific evidence need. They are useful for
- Generating evidence/outcomes
- Understanding the economics of the disease and treatment landscape
- Demonstrating comparative effectiveness
- Supporting deep scientific investigation
The rare disease treatment landscape is complicated and competitive, and sponsors need strategies to help them enhance their submissions and commercial efforts. Taking advantage of the available ‘mosaic’ of clinical and real world components in RWE studies can deliver these benefits. They cut the time and cost of clinical research and provide a more robust picture of the patient journey, and a treatment’s impact on their quality of life and healthcare costs.
IQVIA can help you analyze and understand the ever-expanding ecosystem of clinically rich data in the context of your organization’s needs. By combining advanced analytics with unparalleled data and scientific expertise, IQVIA provides customers with innovative real world evidence approaches to meet stakeholder needs throughout the product lifecycle.
eBook: Explore Transformative RWD Sources
Discover how you can leverage RWE to accelerate study timelines, shorten time to market, cut research costs, and more. In this interactive eBook, read case examples on how key client questions were answered in various therapeutic areas and glean insights on how you can use RWD to answer challenging research questions.